P&K Skin Research Center Co., Ltd.

KOSDAQ:A347740 Stock Report

Market Cap: ₩75.7b

P&K Skin Research Center Past Earnings Performance

Past criteria checks 1/6

P&K Skin Research Center's earnings have been declining at an average annual rate of -11.9%, while the Life Sciences industry saw earnings growing at 31.2% annually. Revenues have been declining at an average rate of 1.9% per year. P&K Skin Research Center's return on equity is 7.1%, and it has net margins of 32.9%.

Key information

-11.9%

Earnings growth rate

-11.1%

EPS growth rate

Life Sciences Industry Growth53.7%
Revenue growth rate-1.9%
Return on equity7.1%
Net Margin32.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We Think That There Are More Issues For P&K Skin Research Center (KOSDAQ:347740) Than Just Sluggish Earnings

Mar 28
We Think That There Are More Issues For P&K Skin Research Center (KOSDAQ:347740) Than Just Sluggish Earnings

Revenue & Expenses Breakdown

How P&K Skin Research Center makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

KOSDAQ:A347740 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2416,2835,3563,9331,457
31 Mar 2415,5004,6974,0661,400
31 Dec 2314,8434,8133,9981,357
30 Sep 2315,7665,3233,9721,508
30 Jun 2316,6026,0803,8051,636
31 Mar 2317,7407,1703,5901,675
31 Dec 2217,9577,1303,4761,670

Quality Earnings: A347740 has high quality earnings.

Growing Profit Margin: A347740's current net profit margins (32.9%) are lower than last year (36.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Unable to establish if A347740's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.

Accelerating Growth: Unable to compare A347740's past year earnings growth to its 5-year average as it has been trading publicly for less than 3 years.

Earnings vs Industry: A347740 had negative earnings growth (-11.9%) over the past year, making it difficult to compare to the Life Sciences industry average (18%).


Return on Equity

High ROE: A347740's Return on Equity (7.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies